BioGeneration Ventures leverages its knowledge gained from working with a diverse network.
This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry.
Learn about the latest developments at BioGeneration Ventures and what’s happening at our portfolio companies.
Our team adopts a hands-on approach. We work closely with our portfolio companies to review transactions that leverage operational and management expertise.
We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process.
Wouter is a venture partner at BGV since 2021. He is currently CEO at Dualyx and will serve in interim management positions in portfolio companies of BGV.
Read more
Rob is venture partner at BGV since 2016, serving on the board and in interim management positions in the fund’s portfolio companies.
Read more
Oskar joined BioGeneration as a partner in 2016 strengthening the team with his commercial, business development and consulting experience.
Read more
Daniela previously was CEO at Cell2B, a life sciences company that she co-founded dedicated to treat immune and inflammatory diseases.
Read more
Lars is a Senior Advisor at BGV. He leads the Centre of Drug Development at CRUK where he oversees the delivery of a portfolio of 20 early stage clinical trials.
Read more
Prof. Dr. John Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam.
Read more
Jason joined Forbion in 2026 as a Venture Partner, bringing 30 years of industry experience spanning drug discovery, translational research, and external innovation across neurology, oncology, and immunology.
Read more
At BGV, Robbert is responsible for Fundraising and Investor Relations. He also leads Forbion’s ESG and impact investing efforts.
Read more
Cyrill is Senior Controller and his main focus lies in the financial and treasury operations as well as the accounting and tax reporting.
Read more
Arnoud is a venture partner with BGV and joined in 2018. He currently holds various positions in the management of BGV portfolio companies including VarmX and Staten Biotechnology.
Read more
Dr. Ritsou brings 20 years of experience in Corporate and Business Development in pharmaceutical and biotech companies.
Read more
